Harmonization of Activity Determination Requirements for Recombinant Blood Clotting Factor rFVIIa


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

The interchangeability of coagulation methods for determining the activity of recombinant blood clotting factor rFVIIa was assessed. Single-factor analysis of variance (ANOVA) and comparison of the metrological characteristics of the methods led to the conclusion that results obtained by reproducing the methods of the European Pharmacopoeia and Generium were comparable and interchangeable. One method could be used to confirm that a drug conformed to regulations established using another method. The Generium method was chosen for introduction into national pharmacopoeial practice because it was more economical.

作者简介

O. Ustinnikova

Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Public Health of the Russian Federation; Generium Inc.

编辑信件的主要联系方式.
Email: Ustinnikova@expmed.ru
俄罗斯联邦, 8/2 Petrovskii Blvd., Moscow, 127051; Moscow

E. Novikova

Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Public Health of the Russian Federation

Email: Ustinnikova@expmed.ru
俄罗斯联邦, 8/2 Petrovskii Blvd., Moscow, 127051

O. Runova

Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Public Health of the Russian Federation

Email: Ustinnikova@expmed.ru
俄罗斯联邦, 8/2 Petrovskii Blvd., Moscow, 127051

D. Shvedov

Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Public Health of the Russian Federation

Email: Ustinnikova@expmed.ru
俄罗斯联邦, 8/2 Petrovskii Blvd., Moscow, 127051

M. Zhilyaeva

Generium International Biotechnology Center

Email: Ustinnikova@expmed.ru
俄罗斯联邦, Moscow, 123317

D. Kudlai

Generium Inc.

Email: Ustinnikova@expmed.ru
俄罗斯联邦, Moscow

补充文件

附件文件
动作
1. JATS XML

版权所有 © Springer Science+Business Media, LLC, 2017